Shandong Xinhua Pharmaceutical Co Ltd
SZSE:000756

Watchlist Manager
Shandong Xinhua Pharmaceutical Co Ltd Logo
Shandong Xinhua Pharmaceutical Co Ltd
SZSE:000756
Watchlist
Price: 16.53 CNY -3.78% Market Closed
Market Cap: ¥11.4B

Net Margin

4.5%
Current
Declining
by 1.1%
vs 3-y average of 5.6%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
4.5%
=
Net Income
¥382.2m
/
Revenue
¥8.5B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
4.5%
=
Net Income
¥382.2m
/
Revenue
¥8.5B

Peer Comparison

Country Company Market Cap Net
Margin
CN
Shandong Xinhua Pharmaceutical Co Ltd
SZSE:000756
11.9B CNY
Loading...
US
Eli Lilly and Co
NYSE:LLY
992.9B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
541.8B USD
Loading...
CH
Roche Holding AG
SIX:ROG
278.2B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
216.3B GBP
Loading...
CH
Novartis AG
SIX:NOVN
223.2B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
269.1B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
151B USD
Loading...
FR
Sanofi SA
PAR:SAN
97.1B EUR
Loading...

Market Distribution

In line with most companies in China
Percentile
54th
Based on 8 721 companies
54th percentile
4.5%
Low
-416 945.9% — -1.5%
Typical Range
-1.5% — 8.9%
High
8.9% — 17 382.1%
Distribution Statistics
China
Min -416 945.9%
30th Percentile -1.5%
Median 3.5%
70th Percentile 8.9%
Max 17 382.1%

Shandong Xinhua Pharmaceutical Co Ltd
Glance View

Market Cap
11.4B CNY
Industry
Pharmaceuticals

In the industrious province of Shandong, China, Shandong Xinhua Pharmaceutical Co. Ltd. emerges as a notable player in the pharmaceutical landscape. Established in 1943, the company has grown into a comprehensive pharmaceutical enterprise with a significant presence both domestically and internationally. At its core, Shandong Xinhua is devoted to the research, development, and manufacture of active pharmaceutical ingredients (APIs), finished dosages, and chemical intermediates. The firm's strength lies in its diverse range of products, with pain management and anti-infectives being standout categories. Their strategic focus on innovation is evident in their state-of-the-art R&D facilities, which fuel continuous product development, ensuring they meet high regulatory standards and cater to evolving market demands. The journey of Shandong Xinhua is one of strategic evolution, with a steadfast commitment to quality and sustainability. This narrative is reflected in their robust revenue streams derived from both domestic sales and the lucrative export markets across over 50 countries. The company's business model hinges on creating value through efficient manufacturing processes and leveraging economies of scale, which enhances their competitive edge in the global market. With an eye on future growth, they've also been investing in digitalization to streamline operations and enhance productivity. As the pharmaceutical sector continues to expand, Shandong Xinhua Pharmaceutical Co. Ltd. is poised to capitalize on emerging opportunities, underpinned by its solid foundation and innovative thrust.

Intrinsic Value
15.77 CNY
Overvaluation 5%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
4.5%
=
Net Income
¥382.2m
/
Revenue
¥8.5B
What is Shandong Xinhua Pharmaceutical Co Ltd's current Net Margin?

The current Net Margin for Shandong Xinhua Pharmaceutical Co Ltd is 4.5%, which is below its 3-year median of 5.6%.

How has Net Margin changed over time?

Over the last 3 years, Shandong Xinhua Pharmaceutical Co Ltd’s Net Margin has decreased from 5% to 4.5%. During this period, it reached a low of 4.5% on Oct 30, 2025 and a high of 6.1% on Mar 31, 2024.

Back to Top